Abstract
Patients with high grade glioma generally have poor prognoses. Addition of radiosensitizing agents might improve the response to irradiation. The chemotherapeutic agent estramustine sensitizes experimental gliomas to radiation. Gliomas express estramustine binding proteins, and cytotoxic concentrations of estramustine metabolites are found in gliomas after oral administration. Twenty three patients, aged 25–78, with new or recurrent high grade glioma were treated with estramustine and radiosurgery and/or radiotherapy. Patients with recurrent tumors were treated with estramustine and Gamma Knife stereotactic radiosurgery; eligible tumors were limited to 4 cm maximal diameter. Patients with newly diagnosed tumors were treated with estramustine and fractionated radiotherapy, with radiosurgery also performed if the tumor was less than 4 cm maximal diameter. Estramustine (16 mg/kg per day orally) was started three days prior to radiosurgery, or, if only radiotherapy was performed, on the first day of radiotherapy. Estramustine was continued until the completion of radiosurgery and/or radiotherapy (72 Gy, 60 fractions, 1.2 Gy bid over 6 weeks). Of the 13 patients treated for newly diagnosed glioblastoma, median survival was 16 months with 38% 2-year survival. Of five patients treated for recurrent glioblastoma, survival was 3, 8, 9, 15, and 23+ months. Two patients with recurrent anaplastic astrocytoma survived for 24 and 48+ months. One patient with recurrent anaplastic mixed glioma survived 5+ months. Two patients with newly diagnosed anaplastic oligodendroglioma survived 20 and 42+ months. Four of the new glioblastoma patients developed deep vein thrombosis. The results of this pilot study indicate some benefit, and further investigation incorporating estramustine into clinical trials is suggested.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Loeffler JS, Alexander E, Shea WM, Wen PY, Fine HA, Kooy HM, Black PM: Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 10: 1379–1385, 1992
Punzi JS, Duax WL, Strong P, Griffin JF, Flocco MM, Z acharias DE, Carrell HL, Tew KD, Glusker JP: Molecular conformation of estramustine and two analogues. Mol Pharmcol 41: 569–576, 1992
Ryu S, Gabel M, Khil MS, Lee YJ, Kim SH, Kim JH: Estramustine: a novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys 30: 99–104, 1994
Yoshida D, Piepmeier J, Weinstein M: Estramustine sensitizes human glioblastoma cells to irradiation. Cancer Res 54: 1415–1417, 1994
Bergenheim AT, Zackrisson B, Elfverson J, Roos G, Henriksson R: Radiosensitizing effect of estramustine in malignant glioma in vitro and in vivo. J Neuro-Oncol 23: 191–200, 1995
Kim JH, Khil MS, Kim SH, Ryu S, Gabel M: Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 29: 555–557, 1994
von Schoultz E, Lundgren E, Henriksson R: Effects of estramustine and its constituents on human malignant glioma cells. Anticancer Res 10: 693–696, 1990
von Schoultz E, Gunnarsson PO, Henriksson R: Uptake, metabolism, and antiproliferative effect of estramustine phosphate in human glioma cell lines. Anticancer Res 9: 1713–1716, 1989
Yoshida D, Noha M, Watanabe K, Bergenheim T, Henriksson R, Teramoto A: The bleb formation of the extracellular pseudopodia; early evidence of mircotubule depolymerization by estramustine phosphate in glioma cell; in vitro study. J Neuro-Oncol 52: 37–47, 2001
von Schoultz E, Bergenheim T, Grankvist K, Henriksson R: Estramustine binding protein in human brain-tumor tissue. J Neurosurg 74: 962–964, 1991
Karlsson AE, Bjork P, Bergenheim AT, Sandstrom J, Hedman H, Henriksson R: Estramustine-binding protein in malignant glioma in rat. J Neuro-Oncol 49: 19–26, 2000
von Schoultz E, Lundblad D, Bergh J, Grankvist K, Henriksson R: Estramustine binding protein and antiproliferative effect of estramustine in human glioma cell lines. Br J Cancer 58: 326–329, 1988
Bergenheim AT, Bjork P, Bergh J, von Schoultz E, Svedberg H, Henriksson R: Estramustine-binding protein and specific binding of the anti-mitotic compound estramustine in astrocytoma. Cancer Res 54: 4974–4979, 1994
Bergenheim AT, Gunnarsson PO, Edman K, von Schoultz E, Hariz MI, Henriksson R: Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans. Br J Cancer 67: 358–361, 1993
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655, 1982
Panda D, Miller HP, Islam K, Wilson L: Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis of its antitumor action. Proc Natl Acad Sci USA 94: 10560–10564, 1997
Johansson M, Bergenheim AT, D'Argy R, Edman K, Gunnarsson PO, Widmark A, Henriksson R: Distribution of estramustine in the BT4C rat glioma model. Cancer Chemother Pharmacol 41: 317–325, 1998
Yoshida D, Cornell-Bell A, Piepmeier JM: Selective antimitotic effects of estramustine correlate with its antimicrotubule properties on glioblastoma and astrocytes. Neurosurgery 34: 863–868, 1994
Yoshida D, Piepmeier JM, Akira T: In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate. Neurosurgery 39: 360–366, 1996
Yoshida D, Piepmeier JM, Bergenheim T, Henriksson R, Teramoto A: Suppression of matrix metalloproteinase-2-mediated cell invasion in U87MG, human glioma cells by anti-microtubule agent: in vitro study. Br J Cancer 77(1): 21–25, 1998
Yoshida D, Hoshino S, Shimura T, Takahashi H, Teramoto A: Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study. J Neuro-Oncol 47: 133–140, 2000
Wang LG, Xiao ML, Kreis W, Budman DR: The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44: 355–361, 1999
Vallbo C, Bergenheim AT, Bergstrom P, Gunnarsson PO, Henriksson R: Apoptotic tumor cell death induced by estramustine in patients with malignant glioma. Clin Cancer Res 4: 87–91, 1998
Valbo C, Bergenheim T, Bergh A, Grankvist K, Henriksson R: DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain – suggesting an apoptotic cell death. Br J Cancer 71: 717–720, 1995
von Shoultz E, Grankvist K, Gustavsson H, Henriksson R: Effects of estramustine on DNA and cell membrane in malignant glioma cells. Acta Oncol 30: 719–723, 1991
Piepmeier JM, Keefe DL, Weinstein MA, Yoshida D, Zielinski J, Lin T T, Zhaochon C, Naftolin F: Estramustine and estrone analogs rapidly and reversibly inhibit deoxyribonucleic acid synthesis and alter morphology in cultured human glioblastoma cells. Neurosurgery 32: 422–431, 1993
Kayser-Gatchalian MC, Kayser K: Thrombosis and intracranial tumors. J Neurol 209: 217–224, 1975
Hamilton MG, Hull RD, Pineo GF: Prophylaxis of venous thromboembolism in brain tumor patients. J Neuro-Oncol 22: 111–126, 1994
Marras LC, Geerts WH, Perry JR: The risk of venous thromboembolism is increased throughout the course of malignant glioma. Cancer 89: 640–646, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Landy, H., Markoe, A., Potter, P. et al. Pilot Study of Estramustine Added to Radiosurgery and Radiotherapy for Treatment of High Grade Glioma. J Neurooncol 67, 215–220 (2004). https://doi.org/10.1023/B:NEON.0000021825.41221.b5
Issue Date:
DOI: https://doi.org/10.1023/B:NEON.0000021825.41221.b5